A clinical research study to test a new investigational medication for women with breast cancer.

The PALOMA-3 Study is a clinical research study for women with HR+/HER2-negative advanced/metastatic breast cancer that has remained after prior endocrine (hormonal) therapy.

The PALOMA-3 Study is being run worldwide to learn more about the safety and effectiveness of an investigational study medication.

Do you qualify for the study?

If you are interested in taking part in the study, there are certain criteria you will need to meet:

  • You are a woman 18 years or older with breast cancer
  • You have been diagnosed with metastatic or locally advanced breast cancer
  • You have an ER-positive and/or PR-positive tumor
  • You have a HER2-negative tumor
  • Your cancer returned on or after hormonal (endocrine) treatment
  • You have not previously taken any CDK inhibitor, fulvestrant or everolimus

Other study requirements (which will be assessed by the study doctor and/or nurse) will also need to be met.